[Featured Stock] SK Bioscience Rises on News of Successful Phase 3 Clinical Trial for COVID Vaccine

The photo is unrelated to the article content. [Image source=Yonhap News]

[Asia Economy Reporter Myung-hwan Lee] SK Bioscience is showing strong performance from the early trading session on the 25th. This is interpreted as a result of news that the Phase 3 clinical trial of the COVID-19 vaccine they are developing has yielded successful results.

As of 9:30 AM on the same day, SK Bioscience is trading at 131,000 KRW, up 2.75% (3,500 KRW) from the previous trading day.

This is attributed to SK Bioscience's announcement that the candidate substance 'GBP510,' which is being developed as a COVID-19 vaccine, has shown successful results. The company disclosed that the Phase 3 clinical trial results of the COVID-19 vaccine (GBP510) confirmed high immunogenicity that meets all Immunobridging criteria after the primary vaccination.

SK Bioscience stated, "It can be estimated to have vaccine efficacy equal to or greater than the high preventive effect confirmed in the AstraZeneca vaccine," adding, "We plan to secure additional safety results and proceed with domestic and overseas approval applications for the indication of COVID-19 disease prevention after primary vaccination with the GBP510 vaccine in adults."

This content was produced with the assistance of AI translation services.